Matrix IntraDose committee review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At Sept. 10 meeting, the FDA Oncology Drugs Advisory Committee votes unanimously that Matrix's IntraDose (cisplatin/epinephrine) was not shown to be safe and effective in treatment of symptomatic recurrent head and neck squamous cell carcinoma in patients not considered curable with surgery or radiotherapy. Committee members expressed doubt about the clinical benefit of the agent and criticized the clinical benefit measurement tool used in IntraDose trials. The panel also voted against accelerated approval by a nine to three vote, with one abstention. The group encouraged Matrix to develop better designed trials with larger patient populations
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.